EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266–283 antitumor response in preclinical glioblastoma models

[Background]: Glioblastoma (GBM) commonly displays epidermal growth factor receptor (EGFR) alterations (mainly amplification and EGFRvIII) and TAT-Cx43266–283 is a Src-inhibitory peptide with antitumor properties in preclinical GBM models. Given the link between EGFR and Src, the aim of this study w...

Full description

Bibliographic Details
Authors: Álvarez-Vázquez, Andrea, San-Segundo, Laura, Cerveró-García, Pilar, Flores-Hernández, Ollauri‑Ibáñez, Claudia, Segura-Collar, Berta, Hubert, Christopher G., Morrison, Gillian, Pollard, Steven M., Lathia, Justin D., Sánchez-Gómez, Pilar, Tabernero, Arantxa
Format: article
Status:Published version
Publication Date:2024
Country:España
Institution:Consejo Superior de Investigaciones Científicas (CSIC)
Repository:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/380871
Online Access:http://hdl.handle.net/10261/380871
Access Level:Open access
Keyword:Cell-penetrating peptides
EGFR
Glioblastoma
NSCs
Src
Description
Summary:[Background]: Glioblastoma (GBM) commonly displays epidermal growth factor receptor (EGFR) alterations (mainly amplification and EGFRvIII) and TAT-Cx43266–283 is a Src-inhibitory peptide with antitumor properties in preclinical GBM models. Given the link between EGFR and Src, the aim of this study was to explore the role of EGFR in the antitumor effects of TAT-Cx43266–283.

Similar Items